Sun Pharmaceutical Industries: SUNP’s Subsidiary Taro Posts Strong Performance.
Taro posted strong sales growth of 13% YoY to USD 157 mn (+6% QoQ), led by new launches with a sharp improvement in adjusted EBITDA to USD 24 mn
242 Views
Pharmaceuticals: US Generic Growth to Stay, Selective on Structural Play
The pharmaceutical sector, emerging from the volatility of the past two post-pandemic and geopolitically tumultuous years, is now on a recovery...
296 Views
Sun Pharma Industries - One-Time Costs Hit Earnings
Adjusting for exceptional items (Rs39,358mn), Sun Pharma’s 4QFY22 net earnings (Rs15,821mn) was slightly lower than expectations
301 Views
Sun Pharma: Strong Performance on All Fronts; Specialty Buoyed
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general...
244 Views
Domestic Formulation / US (ex-Taro) on steady footing
Sun Pharma (SUNP) delivered yet another robust quarterly performance, with the beat on margins led by Domestic Formulation (DF) / Emerging Markets...
172 Views